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The Role of Menin-MLL interaction in Dissociation between Cholestatic Liver Disease and 
Cholangiocarcinoma 
 
Laurent Ehrlich, Chad Hall, Tori Sheppard, Julie Venter, April O’Brien, Terry C. Lairmore, 
Gianfranco Alpini, Shannon Glaser 
 
 Multiple Endocrine Neoplasia type I (MEN1) is a familial cancer syndrome of the 
parathyroid glands, pituitary glands, and pancreatic islet cells.  We have recently shown 
that menin, the protein encoded by MEN1, acts as a tumor suppressor in 
cholangiocarcinoma (CCA).  However, recent evidence points to menin as a positive 
regulator of hepatic fibrosis.  Thus, we sought to compare and contrast the role of menin in 
cholestatic fibrotic disease states against CCA.  Methods:  We treated bile-duct ligation 
(BDL) and MDR2-/- cholestatic mouse models with a menin-MLL (MI-2-2, 20-40 mg/kg, I.P.) 
or vehicle for 1 week before collecting liver samples.  Immunohistochemistry was 
performed to measure intrahepatic bile duct mass (CK-19 staining) and Sirius Red staining 
to quantify collagen deposition.  By real-time PCR, expression of menin and markers for 
proliferation (Ki67) and fibrosis (TGFbeta1, FN1, alpha-SMA, Col1alpha1) was measured.  
Next we sought to understand the effect of menin-MLL interaction on human CCA growth.  
Mz-ChA-1 cells were treated with MI-2-2 (10 microM, 24 hours) and menin expression was 
assessed with real-time PCR and flow cytometry.  Markers of proliferation (Ki67) and 
angiogenesis (VEGF-A/C, VEGFR-2/3, angiopoietins Angpt1/2, and Tie1/2) were 
measured.  Results:  MI-2-2 treatment reduces biliary mass and collagen deposition via 
CK19 and Sirius Red staining in both BDL and MDR2-/- mice.  Expression of proliferative 
and fibrotic markers decreased in pure cholangiocytes isolated from MI-2-2 treated livers 
of these mice as well.  However, Mz-ChA-1 cells treated with MI-2-2 in vitro increased 
expression of proliferative and angiogenic markers.  Conclusion:  The role of menin-MLL 
interaction is dependent on the disease state or model.  While it drives proliferation and 
fibrosis in fibrotic liver diseases, it inhibits human CCA initiation and progression.  
Understanding how menin-MLL functions in various diseases states can help us understand 
how cholestatic liver diseases progress to CCA. 
